George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Good opportunity for distressed seller/s to bail out.
Wouldn’t surprise me if it was just one distressed seller - but a sizeable one.
SP seems to have found support again at 40p.
‘If you have nothing to say, say nothing’.
Seems to sum up the co’s present position. They’ve done their job, or so we hope, so now it’s time to sit tight.
Nothing to suggest they’re not confident. Certainly the major shareholders continue to show strong support.
To Paul Jourdan’s view of the FDA’s behaviour in issuing the October CRL (his Amati VCT fund still holds 25m of these).
Starts at 30.20 mins
https://youtu.be/0nJJIpsI9Uo
‘FDA …dysfunctional…scared of losing $$ funding….’
Whoever’s selling must deserve some sort of award to wait for this low point.
Imho if the FDA find yet another spurious reason for rejecting this breakthrough system, it’ll be the biggest injustice in recent regulatory history.
It’s like the last two years have been a dream.
200m shares are just staying put.
Zzzzz….
TommyD_19,
Thanks for your perspective on the P3 trial - which, oddly, I’ve recommended - because half of me is inclined to give the co. the benefit of the doubt.
The other half is annoyed, firstly with myself for failing to spot the change in Sprinter protocol (I’d have invested much less) and secondly with the co. for overconfidence in going it alone and also going too multi-country.
I am torn between my admiration for Prof Holgate ( with whom I had dealings many years ago) and my distrust of Richard Marsden (the beard was when it began…).
So I guess I’ll watch what develops, with much reduced expectations, but fingers crossed.
HSD,
Yup. That’s how clinical trials usually work.The patient’s under supervision.
How else will you prove superiority to the ‘competition’(SOC) - bearing in mind this is a Phase III - if you simply add one on top of the other? It makes no sense.
A Phase III in asthma would never involve adding say, a novel bronchodilator in top of SOC salbutamol or budesonide. The results would be meaningless.
HSD,
I understand the basics of clinical trials.
The protocols are usually airtight, so when I see no mention of SOC I take it we’re up against placebo - which is what’s stated in this version of SNG018:
https://www.isrctn.com/ISRCTN85436698
What interests me is when (and why) any change was made. And why Marsden et al were so surprised to see just what SOC was comprised of(what were Parexel up to)?
What puzzles me is why there’s no mention of SOC in the US trial protocol.
https://clinicaltrials.gov/ct2/show/NCT04732949
Anyone got any suggestions?